mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients

Summary

Although FOLFIRINOX regimen was recently presented to be effective as adjuvant chemotherapy for resectable pancreatic cancer in selected patients who have good physical condition, there is still insufficient evidence on this regimen in treating resectable pancreatic cancer patients in China. Since for many tumors, different races may show different responses to the same regimen, we design this open phase Ⅱ study to evaluate the the efficacy and safety of mFOLFIRINOX as adjuvant chemotherapy for resectable pancreatic cancer in China.

Eligibility

Inclusion Criteria:

* Histologically confirmed adenocarcinoma of the pancreas without distant metastases.
* Receive radical resection of pancreatic cancer
* No prior cytostatic chemotherapy
* Female and male patients \> 18 and \<=79 years using contraception
* ECOG ≤ 1
* Patient has adequate bone marrow and organ function
* Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L Platelets ≥ 90 x 109/L Hemoglobin ≥ 90 g/L
* Patient has adequate liver function AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is liver metastasis) Serum bilirubin ≤ 1.2 x ULN Creatinine ≤ 1.25 times ULN
* Good compliance
* Written informed consent

Exclusion Criteria:

* Pregnant or lactating women
* Distant metastasis.
* Patients with severe gastrointestinal hemorrhage which need frequent blood transfusions.
* Refuse to take appropriate contraceptive measures (including male patients).
* Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil.
* Severe systemic disease out of control such as unstable or uncompensated respiratory, cardiac, liver, renal diseases.
* Patient has a concurrent malignancy or has a malignancy within 5 years of study enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in situ).
* Psychiatric illness that would prevent the patient from giving informed consent.
* Patient is concurrently using other antineoplastic agent
* Patient has used investigational antineoplastic agent within 4 weeks prior to entry.
* Known HIV-positivity.
* No history of chronic diarrhea, nausea or vomit.
* No ≥ grade 2 sensory peripheral neuropathy.
* A history of transmural myocardial infarction (within 6 months prior to entry), congestive heart failure, and unstable angina.
* Infectious disease or inflammation with body temperature ≥ 38 ℃.

Conditions2

Interventions1

Related trials

• NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer) — Seoul National University Hospital
• Neoadjuvant FOLFIRINOX in the Treatment of Locally Advanced Gastric Cancer — Instituto do Cancer do Estado de São Paulo
• Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5) — Amsterdam UMC, location VUmc
• The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer. — Fondazione Poliambulanza Istituto Ospedaliero
• Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) — Phanes Therapeutics
• Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma — University of Louisville
• Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer — Icahn School of Medicine at Mount Sinai
• Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel — UNC Lineberger Comprehensive Cancer Center

Browse More Trials